FC
NBIX icon

Farringdon Capital’s Neurocrine Biosciences NBIX Stock Holding History

Farringdon Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$423K Buy
+3,211
New +$426K 0.09% 244
2025
Q1 		– Sell
-2,318
Closed -$316K – 514
2024
Q4 		$316K Buy
+2,318
New +$287K 0.13% 264

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Farringdon Capital's NBIX Position: Q1 2026 in Review

Farringdon Capital opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 3,211 shares worth $423K. The stake represents 0.09% of the portfolio and ranks #244 among its holdings. This is a return to the name: Farringdon Capital previously reported a position in NBIX as recently as Q4 2024.

Farringdon Capital first reported a position in NBIX in Q4 2024 and has held it in 2 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Farringdon Capital held 3,211 shares of Neurocrine Biosciences worth $423K as of Q1 2026.
  • Neurocrine Biosciences was a new Farringdon Capital position in Q1 2026.
  • Neurocrine Biosciences made up 0.09% of Farringdon Capital's portfolio in Q1 2026, its #244 holding.
  • Farringdon Capital first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 2 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Farringdon Capital's 13F filing for Q1 2026, filed 15 May 2026.